Genegobio Inc.

Out-Licensing of Innovative Drugs for Overseas Rights: Key Processes and Considerations

We don't just license technology; we unlock its global market potential. Genegobio designs sophisticated IP monetization frameworks that transform scientific discovery into sustainable revenue streams across international jurisdictions.

Our team works carefully in each step to ensure the benifits of our partners. Below is a structured of how we overview a deal in core processes and critical considerations:

​

I. Core Process Framework

​

1. Value Positioning & Strategic Preparation

   • Patent Audit: Verify global coverage of core compound patents, process patents, and indication-specific patents (focus on remaining validity in target markets).

   • Data Package Development: Compile ICH-compliant preclinical/clinical data, CMC documentation, and market potential analysis (epidemiology, competitive landscape).

   • Market Prioritization: Target regulator-friendly regions (e.g., EMA first, then emerging markets) and assess local payer systems (national insurance, private coverage).

2. Partner Screening & Engagement

   • Strategic Matching: Identify partners aligned with product profiles (e.g., oncology-focused firms for cancer therapies).

   • NDA Execution: Secure confidentiality agreements to share data via virtual data rooms (VDRs).

   • Bid Management: Leverage competitive bidding (RFPs) to maximize deal value.

3. Term Negotiation & Deal Structuring

   • Rights Allocation: Define territorial rights, indication-specific licenses, and future development options.

   • Payment Structure​

   • Control Clauses: Retain co-development rights, audit privileges, and quality oversight.

4. Technology Transfer & Compliance Execution

   • Know-How Transfer: Formalize technical transfer agreements (TTAs) covering manufacturing processes, analytical methods, and stability protocols.

   • Regulatory Alignment: Ensure partner submissions meet originator quality standards (e.g., CMC comparability studies).

   • Supply Chain Compliance: Validate API sourcing and excipient suppliers against target-market GMP requirements.

5. Commercialization & Long-Term Governance

   • Sales Accountability: Enforce minimum annual sales commitments to prevent underperformance.

   • Data Feedback Clause: Require real-world data (RWD) sharing for label expansions.

   • Dispute Resolution: Specify arbitration venues (e.g., Singapore International Arbitration Centre) and governing law (e.g., UK or New York law).

​

II. Key Risks & Mitigation Strategies

​

1. IP Vulnerabilities

   • Risk: Patent cliffs or compulsory licensing (e.g., India’s Section 84 challenges).

   • Mitigation: Include "patent challenge penalties" in agreements (e.g., heavy fines for invalidation attempts).

2. Regulatory Uncertainty

   • Risk: Additional bioequivalence (BE) studies due to manufacturing site changes.

   • Mitigation: Conduct process validation batches during tech transfer, with 6–12-month buffer periods.

3. Financial Pitfalls

   • Risk: Transfer pricing tactics reducing net sales and royalty payouts.

   • Mitigation: Define "Net Sales" explicitly (exclude internal overheads but allow VAT/duty deductions).

4. Geopolitical Volatility

   • Risk: Trade restrictions disrupting API supply chains (e.g., US-China tensions).

   • Mitigation: Include force majeure exit clauses and dual-sourcing rights.